Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nonsense-mediated mRNA Decay02:27

Nonsense-mediated mRNA Decay

11.9K
The Upf proteins that carry out nonsense-mediated decay (NMD) are found in all eukaryotic organisms, including humans. Each protein has an individual role, but they need to work in collaboration. Upf1 is an ATP-dependent RNA helicase that unwinds the RNA helix. Because Upf1 can unwind any RNA, Upf2 and Upf3 are required to help Upf1 discriminate between nonsense and normal mRNAs.
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
11.9K
Nonsense-mediated mRNA Decay02:27

Nonsense-mediated mRNA Decay

3.4K
No description available
3.4K
Mutations01:39

Mutations

94.6K
Overview
94.6K
Mutations01:35

Mutations

44.6K
Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.6K
Exon Recombination02:32

Exon Recombination

4.2K
The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes. 
Exon shuffling follows “splice frame rules.” Each exon...
4.2K
Viral Mutations00:36

Viral Mutations

39.9K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ribitol treatment rescues dystroglycanopathy mice with common L276I mutation.

PloS one·2025
Same author

In Vivo Evaluation of Dystrophin Exon Skipping in mdx Mice.

Methods in molecular biology (Clifton, N.J.)·2025
Same author

Improved efficacy of FKRP AAV gene therapy by combination with ribitol treatment for LGMD2I.

Molecular therapy : the journal of the American Society of Gene Therapy·2023
Same author

Altered muscle niche contributes to myogenic deficit in the D2-mdx model of severe DMD.

Cell death discovery·2023
Same author

Altered muscle niche contributes to myogenic deficit in the D2- <i>mdx</i> model of severe DMD.

bioRxiv : the preprint server for biology·2023
Same author

Ribitol alters multiple metabolic pathways of central carbon metabolism with enhanced glycolysis: A metabolomics and transcriptomics profiling of breast cancer.

PloS one·2022

Related Experiment Video

Updated: Feb 8, 2026

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.3K

Antisense therapy corrects nonsense mutation by exon skipping.

Qi Long Lu1, Terence A Partridge

  • 1Muscle Cell Biology, MRC Clinical Science Centre, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.

Discovery Medicine
|August 14, 2010
PubMed
Summary

Antisense oligonucleotides (AO) can modify gene expression and splicing. This technology, initially used for viral gene knockdown, now offers therapeutic potential for genetic diseases like beta-thalassemia and Duchenne muscular dystrophy.

More Related Videos

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells
06:20

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

Published on: May 7, 2020

7.5K
Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

19.3K

Related Experiment Videos

Last Updated: Feb 8, 2026

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.3K
Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells
06:20

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

Published on: May 7, 2020

7.5K
Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

19.3K

Area of Science:

  • Molecular Biology
  • Genetics
  • Biotechnology

Background:

  • Antisense technology utilizes antisense oligonucleotides (AO) to modulate gene expression at the RNA level.
  • Early applications focused on mRNA targeting for gene knockdown, proving useful in laboratory settings and for viral infections.
  • Recent advancements enable AO to interfere with pre-mRNA splicing, opening new therapeutic avenues.

Purpose of the Study:

  • To explore the application of antisense technology in correcting aberrant gene splicing.
  • To demonstrate the potential of AO in treating genetic disorders caused by splicing defects.

Main Methods:

  • Designing specific antisense oligonucleotides (AO) to target cryptic splice sites in pre-mRNA.
  • Utilizing AO to block the recognition of aberrant splice sites, thereby restoring normal splicing patterns.
  • Investigating AO for selective exon skipping to correct disease-causing mutations.

Main Results:

  • Successfully demonstrated in vitro correction of altered exon splicing in beta-thalassemia by blocking cryptic splice sites with AO.
  • Showcased the restoration of normal gene splicing patterns, leading to proper protein synthesis.
  • Highlighted the potential of AO for treating genetic disorders such as Duchenne muscular dystrophy (DMD) through exon skipping.

Conclusions:

  • Antisense technology is a versatile tool for both gene expression analysis and therapeutic intervention.
  • AO-mediated modulation of pre-mRNA splicing represents a promising strategy for treating genetic diseases.
  • Further development of antisense technology holds significant therapeutic potential for a range of conditions, including viral infections, cancers, and inherited disorders.